Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
    12.
    发明申请
    Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses 失效
    结晶的1H-咪唑并[4,5-b]吡啶-5-胺,7- [5 - [(环己基甲基氨基) - 甲基] -1H-吲哚-2-基] -2-甲基硫酸盐(1:1) 三水合物及其制药用途

    公开(公告)号:US20060194833A1

    公开(公告)日:2006-08-31

    申请号:US11344534

    申请日:2006-02-01

    IPC分类号: C07D471/02 A61K31/4745

    CPC分类号: C07D471/04

    摘要: The invention relates to crystalline 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate, E6070, its method of preparation, and its therapeutic uses. Pharmaceutical compositions containing crystalline E6070 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E6070.

    摘要翻译: 本发明涉及结晶1H-咪唑并[4,5-b]吡啶-5-胺,7- [5 - [(环己基甲基氨基)甲基] -1H-吲哚-2-基] -2-甲基硫酸盐(1 :1),三水合物,E6070,其制备方法及其治疗用途。 含有结晶E6070和药学上可接受的载体的药物组合物代表本发明的一个实施方案。 本发明还涉及用于治疗炎症性疾病,自身免疫性疾病或增殖性疾病的方法,包括向有需要的患者施用治疗有效量的结晶E6070的步骤。